Company intelligence / Profile preview
EnFuego Therapeutics, Inc.
Pittsboro, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
EnFuego Therapeutics develops RNAi-based therapeutics to silence oncogenic gene mutations in cancer, focusing on previously "undruggable" targets such as KRAS. Their lead candidate, EFTX‑001, has shown potent silencing of multiple clinically relevant KRAS mutations in preclinical lung cancer models with no detectable toxicity using an FDA-approved lipid nanoparticle delivery system. The company has received SBIR Phase I and II awards and continues to advance its pipeline through preclinical studies.[1][3]
- Therapeutic areas
- Oncology
- Modalities
- RNA interference (RNAi)small interfering RNA (siRNA)antisense oligonucleotides[1][6]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on EnFuego Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnFuego Therapeutics, Inc..